Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes

Authors

  • Y.-F. Shi,

    Corresponding author
    1. Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China,
    Search for more papers by this author
  • C.-Y. Pan,

    1. Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China,
    2. Department of Endocrinology, Beijing 301 Hospital, Beijing, China,
    Search for more papers by this author
  • J. Hill,

    1. Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China,
    2. Roche Products Pty Ltd, Dee Why, New South Wales, Australia and
    Search for more papers by this author
  • Y. Gao

    1. Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China,
    2. Department of Endocrinology, Peking University First Hospital, Beijing, China
    Search for more papers by this author

Correspondence to: Prof. Yi-Fan Shi MD, No. 1 Shuai Fu Yuan, Department of Endocrinology, Peking Union Medical College Hospital, Beijing 100730, China. E-mail: zhuhj@95777.com

Abstract

Aims  Orlistat promotes weight loss in overweight and obese patients with Type 2 diabetes receiving hypoglycaemic treatment, but has not been investigated in patients with newly diagnosed and previously untreated Type 2 diabetes. We evaluated the efficacy of 24 weeks’ treatment with orlistat, combined with a mildly reduced-calorie diet, on weight loss and glycaemic control in overweight and obese patients with newly diagnosed and previously untreated Type 2 diabetes.

Methods  A total of 249 Chinese patients (body mass index 25–40 kg/m2) with recently diagnosed Type 2 diabetes were randomized to placebo (n = 124) or orlistat 120 mg (n = 125) three times daily; all patients followed a mildly reduced-calorie diet. Patients had HbA1c 6.5–8.5% (mean 7.3%) and had never received any glucose-lowering medication.

Results  Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (−5.4 vs. −2.4 kg; P < 0.0001). More orlistat than placebo patients lost ≥ 5% (60.5 vs. 26.8%; P < 0.0001) and ≥ 10% of their body weight (20.2 vs. 4.9%; P = 0.0002). A significantly greater decrease in HbA1c from baseline was obtained with orlistat than placebo (−1.0 vs. −0.6%; P = 0.0008). Orlistat-treated patients achieved a significantly greater decrease in fasting plasma glucose (−1.3 vs. −0.5 mmol/l; P = 0.0003) and in the 2-h oral glucose tolerance test (−4.1 vs. −1.4 mmol/l; P < 0.0001) than placebo recipients. Also, more orlistat- than placebo-treated patients improved from diabetic status to normal or impaired glucose tolerance (44.3 vs. 32.5%; P = 0.0763) after 24 weeks. Orlistat also produced improvements in lipid profiles and waist circumference.

Conclusions  In combination with a mildly reduced-calorie diet, orlistat significantly reduces body weight, and improves glycaemic control and several cardiovascular risk factors in overweight and obese Chinese patients with newly diagnosed Type 2 diabetes.

Ancillary